Zobrazeno 1 - 10
of 232
pro vyhledávání: '"Lori M, Minasian"'
Autor:
Goli Samimi, Sarah M. Temkin, Carol J. Weil, Paul K. J. Han, Elyse LeeVan, Wendy S. Rubinstein, Tessa M. Swigart, Sarah Caban, Katherine Dent, Lori M. Minasian
Publikováno v:
Cancer Medicine, Vol 13, Iss 21, Pp n/a-n/a (2024)
ABSTRACT Introduction Multicancer detection tests (MCDs) are blood‐based tests designed to detect multiple cancer types. It is currently unclear whether these cancer screening tests improve mortality. To understand awareness of MCDs among providers
Externí odkaz:
https://doaj.org/article/8af4b122485e439e95b0fe67a5257ccc
Autor:
Mitchell J. Machiela, Wen-Yi Huang, Wendy Wong, Sonja I. Berndt, Joshua Sampson, Jonas De Almeida, Mustapha Abubakar, Jada Hislop, Kai-Ling Chen, Casey Dagnall, Norma Diaz-Mayoral, Mary Ferrell, Michael Furr, Alex Gonzalez, Belynda Hicks, Aubrey K. Hubbard, Amy Hutchinson, Kevin Jiang, Kristine Jones, Jia Liu, Erikka Loftfield, Jennifer Loukissas, Jerome Mabie, Shannon Merkle, Eric Miller, Lori M. Minasian, Ellen Nordgren, Brian Park, Paul Pinsky, Thomas Riley, Lorena Sandoval, Neeraj Saxena, Aurelie Vogt, Jiahui Wang, Craig Williams, Patrick Wright, Meredith Yeager, Bin Zhu, Claire Zhu, Stephen J. Chanock, Montserrat Garcia-Closas, Neal D. Freedman
Publikováno v:
Scientific Data, Vol 10, Iss 1, Pp 1-12 (2023)
Abstract The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a prospective cohort study of nearly 155,000 U.S. volunteers aged 55–74 at enrollment in 1993–2001. We developed the PLCO Atlas Project, a large resource for mul
Externí odkaz:
https://doaj.org/article/18e9cf5db56e4fb2a19dac1e5bed4a75
Autor:
Lori M. Minasian, MD, Eileen Dimond, RN, MS, Myrtle Davis, DVM, PhD, ATS, Bishow Adhikari, PhD, Richard Fagerstrom, PhD, Carol Fabian, MD, Justin Floyd, DO, Joseph M. Unger, PhD, MS, Pamela S. Douglas, MD, Karen M. Mustian, PhD, MPH, Eric J. Chow, MD, MPH, Steven Lipshultz, MD, W. Gregory Hundley, MD, Saro H. Armenian, DO, MPH, Bonnie Ky, MD, MSCE
Publikováno v:
JACC. CardioOncology, Vol 1, Iss 1, Pp 105-113 (2019)
Cardiovascular (CV) toxicity from cancer therapy is a significant and growing concern. Conventional oncology clinical trial designs focused solely on cancer treatment efficacy have not provided sufficient information on both CV risk factors and outco
Externí odkaz:
https://doaj.org/article/c9974a1a47d043b78c7cfd5e8ff19334
Autor:
Lori M. Minasian, A. Lindsay Frazier, Lillian Sung, Ann O’Mara, Joseph Kelaghan, Kay W. Chang, Mark Krailo, Brad H. Pollock, Gregory Reaman, David R. Freyer
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 2951-2959 (2018)
Abstract Cisplatin is an essential chemotherapeutic agent in the treatment of many pediatric cancers. Unfortunately, cisplatin‐induced hearing loss (CIHL) is a common, clinically significant side effect with life‐long ramifications, particularly
Externí odkaz:
https://doaj.org/article/7b1f627d4f434d8ea2a66c7a68b0d1e1
Autor:
Lori M Minasian, Paul Pinsky, Hormuzd A Katki, Tony Dickherber, Paul K J Han, Lyndsay Harris, Christos Patriotis, Sudhir Srivastava, Carol J Weil, Philip C Prorok, Philip E Castle
Publikováno v:
JNCI: Journal of the National Cancer Institute. 115:250-257
Blood-based assays using various technologies and biomarkers are in commercial development for the purpose of detecting multiple cancer types concurrently at an early stage of disease. These multicancer early detection (MCED) assays have the potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb1a722b004247eb7b2aed2f2669c7a
https://doi.org/10.1093/jnci/djac218
https://doi.org/10.1093/jnci/djac218
Publikováno v:
Patient Related Outcome Measures. 13:249-258
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9c62f27373a89af420bbfd7f80f1eb1
https://doi.org/10.2147/prom.s256567
https://doi.org/10.2147/prom.s256567
Autor:
Bishow B, Adhikari, Scarlet, Shi, Eileen P, Dimond, Nonniekaye, Shelburne, Patrice, Desvigne-Nickens, Lori M, Minasian
Publikováno v:
Heart Fail Clin
Advances in cancer treatments have led to nearly 17 million survivors in the US today. Cardiovascular complications attributed to cancer treatments are the leading cause of morbidity and mortality in cancer survivors. In response, NCI and NHLBI held
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::44d4c9f4c9ee42e9c54f08355af2794e
https://pubmed.ncbi.nlm.nih.gov/35718423
https://pubmed.ncbi.nlm.nih.gov/35718423
Autor:
Bishow B. Adhikari, Scarlet Shi, Eileen P. Dimond, Nonniekaye Shelburne, Patrice Desvigne-Nickens, Lori M. Minasian
Publikováno v:
Heart Failure Clinics. 18:515-528
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::164472bf8858f6348f14d4a42437eb2f
https://doi.org/10.1016/j.hfc.2022.01.001
https://doi.org/10.1016/j.hfc.2022.01.001
Autor:
Charles A. Kunos, Jacek Capala, Adam P. Dicker, Benjamin Movsas, Susan Percy Ivy, Lori M. Minasian
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
For nearly 40 years, the U.S. National Cancer Institute (NCI) has funded health-related quality-of-life (HRQOL) and symptom management in oncology clinical trials as a method for including a cancer patient's experience during and after treatment. The
Externí odkaz:
https://doaj.org/article/6ab9a0467e244411be4c8763f953ccbf
Autor:
Lori M. Minasian, Eva Szabo, Leslie G. Ford, Shelley S. Kay, Kisha I. Coa, Bonny Bloodgood Sheppard, Bethany Tennant, Christine Holmberg, Brandy M. Heckman-Stoddard, Goli Samimi
As clinical guidelines for cancer prevention refer individuals to primary care physicians (PCP) for risk assessment and clinical management, PCPs may be expected to play an increasing role in cancer prevention. It is crucial that PCPs are adequately
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ec9907177ff7d5a3b1b7f2d4f725198
https://doi.org/10.1158/1940-6207.c.6547078.v1
https://doi.org/10.1158/1940-6207.c.6547078.v1
